A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer

Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Atsushi, Yoshida, Masamichi, Fujimoto, Hajime, Nakahara, Hiroki, Ito, Kentaro, Nishihama, Kota, Yasuma, Taro, Hataji, Osamu, Taguchi, Osamu, D’Alessandro-Gabazza, Corina N., Gabazza, Esteban C., Kobayashi, Tetsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844677/
https://www.ncbi.nlm.nih.gov/pubmed/29321093
http://dx.doi.org/10.3727/096504018X15151523767752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844677/
https://www.ncbi.nlm.nih.gov/pubmed/29321093
http://dx.doi.org/10.3727/096504018X15151523767752

Ejemplares similares